Omeros Company (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Therapy Transcript

Operator

Good afternoon, and welcome to Omeros Company’s convention name. Right this moment’s name is being recorded on the firm’s request, and a replay will likely be out there on the Omeros web site.

I will now flip the decision over to Jennifer Williams, Investor Relations for Omeros. Please go forward.

Jennifer Williams

Thanks, and good afternoon, everybody. Earlier than we start, please be aware that at present’s dialogue will embrace forward-looking statements relating to Omeros’ operations and belongings, together with its newly accepted drug, YARTEMLEA. Ahead-looking statements relating to YARTEMLEA embrace, with out limitation, expectations and projections relating to anticipated demand, manufacturing capability, business gross sales, reimbursement and growth in further indications.

These and different statements on at present’s name replicate administration’s present expectations and beliefs as of at present and are topic to dangers and uncertainties that might trigger precise outcomes to vary materially. For an in depth dialogue of those dangers and uncertainties, please consult with Danger Components sections in our most up-to-date annual report on Type 10-Okay and our subsequently filed quarterly experiences on Type 10-Q. With that, I will now flip the decision over to Dr. Gregory Demopulos, Chairman and CEO of Omeros.

Gregory Demopulos
Co-Founder, Chairman, CEO & President

Thanks, Jennifer, and good afternoon, everybody. Thanks for becoming a member of us. With me at present are David